Trial Profile
Safety and Efficacy of Favipiravir in COVID-19 Patients with Pneumonia −A randomized, double blind, placebo- controlled study &MINUS
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID-19 pneumonia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ferrer
- 08 Apr 2022 Status changed from recruiting to completed.
- 21 Jul 2021 New trial record